R&D Trends

Bristol-Myers Squibb, Syngene International extend research collaboration

Monday, June 9, 2014 01:56 PM

Bristol-Myers Squibb and Syngene International, a CRO based in India, have announced a five-year extension of their drug discovery and development collaboration in India. Financial terms have not been disclosed.

More... »

WIRB Copernicus Group

arGEN-X, Shire Pharmaceuticals partner for therapeutic antibodies

Friday, June 6, 2014 01:03 PM

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has entered into a long-term strategic alliance with Shire Pharmaceuticals.

More... »

CRF Health eCOA webinar series

EFPIA launches vision for European life sciences strategy

Friday, June 6, 2014 12:56 PM

EFPIA, the European Federation of Pharmaceutical Industries and Associations, has launched a paper outlining steps toward an integrated strategy for the life sciences sector in Europe.

More... »

Report: Synthetic biology market expected to reach $38.7B globally by 2020

Friday, June 6, 2014 12:55 PM

According to a new report by Allied Market Research, the global synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during 2014-2020. Europe occupies the largest share in the global market and would hold on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014-2020.

More... »

Ventana, MedImmune collaborate for immunotherapy clinical trials

Thursday, June 5, 2014 10:30 AM

Ventana Medical Systems, a member of the Roche Group, and MedImmune, the global biologics R&D arm of AstraZeneca, are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that only will enroll patients who express PD-L1 as determined by the VENTANA assay.

More... »

CEOi, Sage Bionetworks, DREAM Project launch Alzheimer’s big data challenge

Wednesday, June 4, 2014 01:19 PM

The Global CEO Initiative on Alzheimer’s disease (CEOi), nonprofit biomedical research organization Sage Bionetworks and the DREAM Project have launched the Alzheimer’s Disease Big Data DREAM Challenge #1, in an effort to advance diagnostic innovation and identify new Alzheimer’s disease biomarkers through the use of open source data.

More... »

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner

Tuesday, June 3, 2014 01:23 PM

Memorial Sloan Kettering (MSK) Cancer Center and Quest Diagnostics, a provider of diagnostic information services, have formed a joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors.

More... »

Qiagen, Eli Lilly collaborate to co-develop companion diagnostics

Tuesday, June 3, 2014 11:17 AM

Qiagen, a Netherlands-based holding company, is collaborating with Eli Lilly to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on Qiagen's multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.   

More... »

Dako, Merck to collaborate on companion diagnostic test

Tuesday, June 3, 2014 10:15 AM

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, is collaborating with Merck to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer.

More... »

Aduro inks agreement with Janssen Biotech for prostate cancer candidates

Friday, May 30, 2014 01:39 PM

Aduro BioTech, a clinical-stage biotechnology company, has entered into an agreement granting Janssen Biotechan exclusive worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. The agreement is facilitated by the Johnson & Johnson Innovation center in California. Aduro is eligible to receive up to $365 million in upfront license fees and milestone payments upon achievement of defined development, regulatory and commercialization milestones, if multiple programs advance to commercialization, as well as tiered royalties on worldwide net sales.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs